Mabwell(SH:688062) Shang Hai Zheng Quan Bao·2025-09-17 19:51Group 1 - The company signed an exclusive licensing agreement with Kalexo Bio, Inc. for the 2MW7141 project, which includes a total potential payment of up to $1 billion, consisting of upfront and milestone payments, as well as low single-digit royalties [2][5][11] - The agreement is expected to positively impact the company's future performance and enhance its profitability [3][11] - The 2MW7141 project is a dual-target small nucleic acid drug in the preclinical stage, aimed at regulating blood lipids and preventing high-risk cardiovascular events [6][7] Group 2 - The licensing agreement allows Kalexo exclusive rights for the global development, production, and commercialization of the licensed product [8] - The agreement includes a one-time, non-refundable upfront payment of $12 million in cash, and the company will also receive a total of double-digit A-round preferred shares from Kalexo under certain conditions [2][8] - The agreement is governed by New York law and interpreted according to California law [9] Group 3 - The company aims to leverage the collaboration with Kalexo to provide innovative treatment options for global patients, enhancing its brand value and international influence [11] - The agreement will not change the company's main business or operational scope and will not affect its independence [11]